(P-386) A Phase 4 Study to Evaluate the Safety and Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Co-Author(s)

SW

Sharon Walmsley, MSc, MD, FRCPC

University Health Network
Toronto, Ontario, Canada
Moti Ramgopal, MD

Medical Director
Midway Immunology and Research Center
Fort Pierce, Florida, United States
TM

Thomas CS Martin, MD

Assistant Professor of Medicine
University of California San Diego
La Jolla, California, United States
JH

Jason Hindman, PharmD, MBA

Gilead Sciences
Foster City, California, United States
HL

Hui Liu, PhD

Director
Gilead Sciences, Inc., Foster City, CA, USA
Foster City, California, United States
KA

Keith Aizen, MD

Gilead Sciences, Inc.
Foster City, California, United States
JO

Jason F. Okulicz, MD

Gilead Sciences, Inc.
Foster City, New Jersey, United States

Samir K. Gupta, MD (he/him/his)

Professor of Medicine
Indiana University School of Medicine
Indianapolis, IN, United States